Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - KalVista Pharmaceuticals, Inc. | kalv-ex322_10.htm |
| EX-32.1 - EX-32.1 - KalVista Pharmaceuticals, Inc. | kalv-ex321_9.htm |
| EX-31.2 - EX-31.2 - KalVista Pharmaceuticals, Inc. | kalv-ex312_17.htm |
| EX-31.1 - EX-31.1 - KalVista Pharmaceuticals, Inc. | kalv-ex311_16.htm |
| EX-21.1 - EX-21.1 - KalVista Pharmaceuticals, Inc. | kalv-ex211_127.htm |
| EX-3.4 - EX-3.4 - KalVista Pharmaceuticals, Inc. | kalv-ex34_587.htm |
| 10-K - 10-K - KalVista Pharmaceuticals, Inc. | kalv-10k_20200430.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-215185 and 333-228831 on Form S-3 and Registration Statement Nos. 333-203721, 333-215184, 333-216032, 333-217008, 333-226442, 333-230279, and 333-237059 on Form S-8 of our report dated July 1, 2020, relating to the financial statements of KalVista Pharmaceuticals, Inc. appearing in this Annual Report on Form 10-K of KalVista Pharmaceuticals, Inc. for the year ended April 30, 2020.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
July 1, 2020